Skip to main content

Herena Eixarch Ahufinger

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Herena Eixarch Ahufinger

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Valorización de una terapia antígeno-específica para el tratamiento disruptivo de la diabetes tipo 1; esclerosis múltiple, miastenia gravis, enfermedad celíaca y artritis reumatoide.

IP: Carmen Espejo Ruiz
Collaborators: Sara Marsal Barril, Herena Eixarch Ahufinger, Helena Borrell Paños, Maria America Lopez Lasanta
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 217313.9
Reference: CPP2021-008475
Duration: 10/02/2022 - 31/12/2025

Ministerio de Ciencia

Rejuvenation of the immune system as a therapeutic approach for progressive multiple sclerosis.

IP: Carmen Espejo Ruiz
Collaborators: Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI21/01682
Duration: 01/01/2022 - 30/06/2026

Inmunosenescencia en la esclerosis múltiple. La inmunidad innata como posible diana terapéutica en la esclerosis múltiple.

IP: Carmen Espejo Ruiz
Collaborators: Herena Eixarch Ahufinger, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI18/01146
Duration: 01/01/2019 - 30/06/2023

Incorporació Dr. Manuel Comabella a la RETICS en Esclerosis Múltiple

IP: Manuel Comabella Lopez
Collaborators: Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Incorporació Dr. Manuel Comabella a la RETICS en Esclerosis Múltiple, Carmen Espejo Ruiz, Angela Vidal Jordana, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 225500
Reference: RD16/0015/0004
Duration: 01/01/2017 - 31/12/2022

Related news

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

Related professionals

Ana Díez Izquierdo

Ana Díez Izquierdo

Main researcher
Growth and Development
Read more
Maria Garcia Carrasco

Maria Garcia Carrasco

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Marta Comas Martínez

Marta Comas Martínez

Research technician
Diabetes and Metabolism
Read more
Laura Castellote Bellés

Laura Castellote Bellés

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.